{
  "query": "What is the mechanism of cytokine storm syndrome on the COVID-19?",
  "keqe_expansions": [
    "Cytokine storm syndrome in COVID-19 refers to an excessive and dysregulated immune response that can lead to severe inflammation and tissue damage in the body. The mechanism of this syndrome involves a cascade of events triggered by the SARS-CoV-2 virus infecting host cells, primarily in the respiratory tract. The virus activates immune cells, such as T cells and macrophages, prompting them to release large amounts of pro-inflammatory cytokines, particularly interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 (IL-1).\n\nThese cytokines further stimulate immune cells and cause a continuous loop of inflammatory responses, leading to a hyperactive immune state known as a cytokine storm. The excessive release of these inflammatory molecules can damage healthy tissues and organs, contributing to the severity of symptoms seen in COVID-19 patients with cytokine storm syndrome.\n\nFurthermore, the dysregulated immune response can result in a condition called acute respiratory distress syndrome (ARDS), characterized by severe lung inflammation and fluid buildup, ultimately leading to respiratory failure and other complications. Understanding the mechanism behind cytokine storm syndrome in COVID-19 is crucial for developing targeted treatments and therapies to mitigate its harmful effects and improve patient outcomes.",
    "Cytokine storm syndrome in COVID-19 is a hyperinflammatory response triggered by the release of a large number of pro-inflammatory cytokines in the body. When a person is infected with the SARS-CoV-2 virus, the immune system mounts a defense by releasing cytokines to help fight off the infection. In some cases, the immune response becomes dysregulated, leading to an excessive release of cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-\u03b1), and interleukin-1 (IL-1), among others.\n\nThis uncontrolled release of cytokines leads to a cascade of inflammatory reactions throughout the body, causing widespread tissue damage and organ dysfunction. The cytokine storm syndrome can result in a hyperactivated immune response that attacks healthy tissues along with the viral-infected cells, leading to severe complications and potentially fatal outcomes in some COVID-19 patients.\n\nThe mechanisms underlying cytokine storm syndrome in COVID-19 are complex and multifactorial, involving interactions between the virus, the host immune system, and various other factors. Understanding these mechanisms is crucial for developing effective treatment strategies to modulate the immune response and prevent the cytokine storm syndrome from causing severe harm to patients with COVID-19."
  ],
  "csqe_expansions": [
    "What is the mechanism of cytokine storm syndrome on the COVID-19? One of the most important mechanisms underlying the deterioration of the disease is cytokine storm. Some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm. One of the most important mechanisms underlying the deterioration of the disease is cytokine storm. Some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm. Cytokine release syndrome (or 'cytokine storm') is likely to be a contributing factor to ARDS in many patients. Interleukin 6 (IL-6) is known to play a key role in inflammation, IL-6 receptor inhibitors such as tocilizumab may potentially treat COVID-19 by. The severity and mortality of the disease is associated with a high level of release of cytokines in the patients, known as CRS (cytokine release syndrome) or cytokine storm syndrome. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane-bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT signaling pathway. Cytokine storm is an important factor leading to rapid disease progression in COVID-19. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19. Immunologic complications such as macrophage activation syndrome resulting in cytokine storm syndrome and acute respiratory distress syndrome may occur in some patients. Impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm.",
    "What is the mechanism of cytokine storm syndrome on the COVID-19?, One of the most important mechanisms underlying the deterioration of disease is cytokine storm. Therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm with some progresses being achieved. One of the most important mechanisms underlying the deterioration of disease is cytokine storm. Some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm and have made some progress. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane-bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT signaling pathway."
  ],
  "top_passages": [
    "[Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019]\tCoronavirus disease 2019 (COVID-19) has seriously affected the safety of patients and social stability. Some COVID-19 patients in the later stage of disease may develop into acute respiratory distress syndrome or even multiple organ failure. However, one of the most important mechanisms underlying the deterioration of disease is cytokine storm. At present, some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm with some progresses being achieved. This article reviews the influences of cytokine storm syndrome on the COVID-19 and the corresponding immunotherapies to",
    "[Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies]\tCorona Virus Disease 2019 (COVID-19) has seriously affected the treatment of patients and social stability. In the later stage of disease, some COVID-19 patients may develop into acute respiratory distress syndrome or even multiple organ failure. However, one of the most important mechanism underlying the deterioration of disease is cytokine storm. At present, some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm and have made some progress. This article reviews the influences of cytokine storm syndrome on the COVID-19 and the corresponding",
    "[Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies].\tCorona Virus Disease 2019 (COVID-19) has seriously affected the treatment of patients and social stability. In the later stage of disease, some COVID-19 patients may develop into acute respiratory distress syndrome or even multiple organ failure. However, one of the most important mechanism underlying the deterioration of disease is cytokine storm. At present, some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm and have made some progress. This article reviews the influences of cytokine storm syndrome on the COVID-19 and the",
    "Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review\tCOVID-19, caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, in 2019 and has resulted in the current pandemic The disease continues to pose a major therapeutic challenge Patient mortality is ultimately caused by acute respiratory distress syndrome (ARDS) Cytokine release syndrome (or \"cytokine storm\") is likely to be a contributing factor to ARDS in many patients Because interleukin 6 (IL-6) is known to play a key role in inflammation, IL-6 receptor inhibitors such as tocilizumab may potentially treat COVID-19 by",
    "The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of \u201cinflame-aging\u201d\tPURPOSE: Novel Coronavirus disease 2019 (COVID-19), is an acute respiratory distress syndrome (ARDS), which is emerged in Wuhan, and recently become worldwide pandemic. Strangely, ample evidences have been shown that the severity of COVID-19 infections varies widely from children (asymptomatic), adults (mild infection), as well as elderly adults (deadly critical). It has proven that COVID-19 infection in some elderly critical adults leads to a cytokine storm, which is characterized by severe systemic elevation of several pro-inflammatory cytokines. Then, a cytokine storm",
    "The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of \"inflame-aging\"\tPURPOSE: Novel Coronavirus disease 2019 (COVID-19), is an acute respiratory distress syndrome (ARDS), which is emerged in Wuhan, and recently become worldwide pandemic. Strangely, ample evidences have been shown that the severity of COVID-19 infections varies widely from children (asymptomatic), adults (mild infection), as well as elderly adults (deadly critical). It has proven that COVID-19 infection in some elderly critical adults leads to a cytokine storm, which is characterized by severe systemic elevation of several pro-inflammatory cytokines. Then, a cytokine storm",
    "Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19\tAbstract Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT signaling pathway. It",
    "Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia\tSince December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that \u2053 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19",
    "Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment\tCOVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic",
    "Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment\tCOVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic"
  ],
  "combined_expansion": "What is the mechanism of cytokine storm syndrome on the COVID-19? What is the mechanism of cytokine storm syndrome on the COVID-19? Cytokine storm syndrome in COVID-19 refers to an excessive and dysregulated immune response that can lead to severe inflammation and tissue damage in the body. The mechanism of this syndrome involves a cascade of events triggered by the SARS-CoV-2 virus infecting host cells, primarily in the respiratory tract. The virus activates immune cells, such as T cells and macrophages, prompting them to release large amounts of pro-inflammatory cytokines, particularly interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 (IL-1).\n\nThese cytokines further stimulate immune cells and cause a continuous loop of inflammatory responses, leading to a hyperactive immune state known as a cytokine storm. The excessive release of these inflammatory molecules can damage healthy tissues and organs, contributing to the severity of symptoms seen in COVID-19 patients with cytokine storm syndrome.\n\nFurthermore, the dysregulated immune response can result in a condition called acute respiratory distress syndrome (ARDS), characterized by severe lung inflammation and fluid buildup, ultimately leading to respiratory failure and other complications. Understanding the mechanism behind cytokine storm syndrome in COVID-19 is crucial for developing targeted treatments and therapies to mitigate its harmful effects and improve patient outcomes. Cytokine storm syndrome in COVID-19 is a hyperinflammatory response triggered by the release of a large number of pro-inflammatory cytokines in the body. When a person is infected with the SARS-CoV-2 virus, the immune system mounts a defense by releasing cytokines to help fight off the infection. In some cases, the immune response becomes dysregulated, leading to an excessive release of cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-\u03b1), and interleukin-1 (IL-1), among others.\n\nThis uncontrolled release of cytokines leads to a cascade of inflammatory reactions throughout the body, causing widespread tissue damage and organ dysfunction. The cytokine storm syndrome can result in a hyperactivated immune response that attacks healthy tissues along with the viral-infected cells, leading to severe complications and potentially fatal outcomes in some COVID-19 patients.\n\nThe mechanisms underlying cytokine storm syndrome in COVID-19 are complex and multifactorial, involving interactions between the virus, the host immune system, and various other factors. Understanding these mechanisms is crucial for developing effective treatment strategies to modulate the immune response and prevent the cytokine storm syndrome from causing severe harm to patients with COVID-19. What is the mechanism of cytokine storm syndrome on the COVID-19? One of the most important mechanisms underlying the deterioration of the disease is cytokine storm. Some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm. One of the most important mechanisms underlying the deterioration of the disease is cytokine storm. Some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm. Cytokine release syndrome (or 'cytokine storm') is likely to be a contributing factor to ARDS in many patients. Interleukin 6 (IL-6) is known to play a key role in inflammation, IL-6 receptor inhibitors such as tocilizumab may potentially treat COVID-19 by. The severity and mortality of the disease is associated with a high level of release of cytokines in the patients, known as CRS (cytokine release syndrome) or cytokine storm syndrome. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane-bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT signaling pathway. Cytokine storm is an important factor leading to rapid disease progression in COVID-19. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19. Immunologic complications such as macrophage activation syndrome resulting in cytokine storm syndrome and acute respiratory distress syndrome may occur in some patients. Impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. What is the mechanism of cytokine storm syndrome on the COVID-19?, One of the most important mechanisms underlying the deterioration of disease is cytokine storm. Therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm with some progresses being achieved. One of the most important mechanisms underlying the deterioration of disease is cytokine storm. Some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm and have made some progress. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane-bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT signaling pathway."
}